A pre-post trial to examine biological mechanisms of the effects of time-restricted eating on symptoms and quality of life in bipolar disorder.

Autor: Johnson SL; Department of Psychology, University of California, Berkeley, CA, USA., Murray G; Centre for Mental Health, Swinburne University, Melbourne, VIC, 3122, Australia., Manoogian ENC; Salk Institute for Biological Studies, La Jolla, CA, USA., Mason L; Research Department of Clinical, Educational and Health Psychology, University College London, London, UK., Allen JD; Department of Psychology, University of California, Berkeley, CA, USA., Berk M; IMPACT Institute, School of Medicine, Deakin University, Geelong, VIC, Australia., Panda S; Salk Institute for Biological Studies, La Jolla, CA, USA., Rajgopal NA; Department of Psychology, University of California, Berkeley, CA, USA., Gibson JC; Department of Psychology, University of California, Berkeley, CA, USA., Bower CD; Department of Psychology, University of California, Berkeley, CA, USA., Berle EF; Department of Psychology, University of California, Berkeley, CA, USA., Joyner K; Department of Psychology, University of California, Berkeley, CA, USA., Villanueva R; Department of Psychology, University of California, Berkeley, CA, USA., Michalak EE; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada., Kriegsfeld LJ; Department of Psychology, University of California, Berkeley, CA, USA. Kriegsfeld@berkeley.edu.; Department of Neuroscience, University of California, Berkeley, CA, USA. Kriegsfeld@berkeley.edu.
Jazyk: angličtina
Zdroj: BMC psychiatry [BMC Psychiatry] 2024 Oct 21; Vol. 24 (1), pp. 711. Date of Electronic Publication: 2024 Oct 21.
DOI: 10.1186/s12888-024-06157-5
Abstrakt: Background: The primary objective of this trial is to examine the mechanisms of time-restricted eating (TRE) as an adjunct to psychiatric care for people with bipolar disorder (BD) with sleep or circadian disruptions. This study builds on prior studies of circadian disruption in BD as well as growing evidence that TRE improves circadian functioning.
Methods: One-hundred fifty participants diagnosed with BD 1 or II will be recruited via advertising in the local community. Main inclusion criteria include: obtaining medical treatment for BD; current sleep or circadian problems; self-reported eating period of ≥ 12 h; no eating disorder or other health conditions that would hinder or limit the safety of following TRE; and not currently experiencing a mood episode, acute suicidality, psychosis, alcohol or substance use disorder. Participants will be asked to complete a baseline period in which daily food intake is logged online for two weeks. After baseline, participants will be asked to follow TRE for 8 weeks and to continue to complete daily food logging during this time. Symptom severity interviews will be conducted by phone or videoconference at baseline, mid-intervention (6 weeks post-baseline), end of intervention (10 weeks post-baseline), and 6 months post-baseline. Self-rated symptom severity and quality of life data will be gathered online at the same time points as symptom severity interviews, and at 16 weeks post-baseline (6 weeks after the TRE period ends). To assess potential mechanisms of change, we will examine the change in diurnal amplitude of 'clock' gene expression as a primary mediator at 8 weeks compared to baseline. We will further test whether diurnal amplitude of clock gene expression is predictive above and beyond the role of two covariate potential mediators, glucose tolerance and inflammation at 8 weeks relative to baseline. To provide an index of whether TRE successfully decreases emotional lability, participants will be asked to complete 5 mood assessments per day for 7 days at baseline and at 10 weeks. These mood assessments will be optional.
Discussion: The planned research will provide novel and important information on whether TRE improves sleep/circadian rhythm problems, along with reductions in mood symptoms and improvements in quality of life, for individuals with BD.
Trial Registration: ClinicalTrials.gov ID: NCT06555406.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje